NCT07174349 - Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Urinary Retention Postoperative

Interventions

DRUG

Uroselective alpha-1-adrenergic receptor antagonist

Subjects will receive Tamsulosin (0.4 mg daily) beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)

OTHER

Placebo

Subjects will receive placebo beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester